Dr. Al Baghdadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5303 Elliott Dr
Suite 210
Ypsilanti, MI 48197Phone+1 734-712-1000Fax+1 734-222-3100
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2004 - 2007
Damascus University Faculty of MedicineClass of 2002
Certifications & Licensure
MI State Medical License 2007 - 2027
IN State Medical License 2008 - 2013
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 90 citationsPhase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MA...Karen L Reckamp, Mary W Redman, Konstantin H Dragnev, Katherine Minichiello, Liza C Villaruz
Journal of Clinical Oncology. 2022-07-20 - 16 citationsPhase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.Taofeek K. Owonikoko, Mary W. Redman, Lauren Averett Byers, Fred R. Hirsch, Philip C. Mack
Clinical Lung Cancer. 2021-01-10 - 189 citationsA Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel
Clinical Cancer Research. 2020-05-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
